VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.
A pediatric dosing tool developed by the World Health Organization might assist in the design of clinical trials for dosing in children.
The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.
"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.
"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.